Recent studies have shown that PD-1 inhibitors combined with CTLA-4 prolong OS in advanced refractory CRC (38), which confirmed that combining multiple ICIs may be a hot topic for future research in this field. This evidence concerns the gene CTLA4 and colorectal carcinoma.